- Home
- INMB vs RNTX Comparison
INMB vs RNTX Comparison
Compare INMB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | RNTX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.1M | 35.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMB | RNTX |
|---|---|---|
| Price | $1.59 | $1.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $4.30 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 488.2K | 256.8K |
| Earning Date | 10-30-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | $14,337.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $1.02 |
| 52 Week High | $11.64 | $3.50 |
Technical Indicators
Market Signals| Indicator | INMB | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 31.45 |
| Support Level | $1.75 | $1.02 |
| Resistance Level | $1.90 | $1.47 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 0.00 | 5.56 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About RNTX Rein Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.